Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Guldane Cengiz Seval, Klara Dalva, Dilek Oz, Sule Mine Bakanay, Ender Soydan, Gunhan Gurman, Osman Ilhan, Meral Beksac

Blood (2021) 138 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2021-148879

Published: 2021

Journal Articles

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

Güllü Görgün, Elisabetta Calabrese, Ender Soydan, Teru Hideshima, Giulia Perrone, Madhavi Bandi, Diana Cirstea, Loredana Santo, Yiguo Hu, Yu-Tzu Tai, Sabikun Nahar, Naoya Mimura, Claire Fabre, Noopur Raje, Nikhil Munshi, Paul Richardson, Kenneth C. Anderson

Blood (2010) 116 (17): 3227–3237.

https://doi.org/10.1182/blood-2010-04-279893

Published: 2010

Includes: Supplemental data

Journal Articles

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells

Yu-Tzu Tai, Ender Soydan, Weihua Song, Mariateresa Fulciniti, Kihyun Kim, Fangxin Hong, Xian-Feng Li, Peter Burger, Matthew J. Rumizen, Sabikun Nahar, Klaus Podar, Teru Hideshima, Nikhil C. Munshi, Giovanni Tonon, Ruben D. Carrasco, Daniel E. H. Afar, Kenneth C. Anderson

Blood (2009) 113 (18): 4309–4318.

https://doi.org/10.1182/blood-2008-10-183772

Published: 2009

Journal Articles

CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs)

Yu-Tzu Tai, PhD, Ender Soydan, Mariateresa Fulciniti, Weihua Song, Xian-Feng Li, Peter Burger, Fangxin Hong, Giovanni Tonon, Kihyun Kim, Mathew J. Rumizen, Sabikun Nahar, Klaus Podar, Dharminder Chauhan, Teru Hideshima, Daniel R. Carrasco, Nikhil C Munshi, Daniel Afar, PhD, Kenneth C. Anderson

Blood (2008) 112 (11): 840.

https://doi.org/10.1182/blood.V112.11.840.840

Published: 2008

Journal Articles

Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Vildan Ozkocaman, MD, Pervin Topcuoglu, MD, Berna Evranos, MD, Merih Kizil, MD, Aynur U. Bilgin, MD, Mutlu Arat, MD, Muhit Ozcan, MD, Onder Arslan, MD, Gunhan Gurman, MD, Osman Ilhan, MD

Blood (2007) 110 (11): 5096.

https://doi.org/10.1182/blood.V110.11.5096.5096

Published: 2007

Journal Articles

Two Independent Effects of Immunoglobulin-Like Receptor (KIR) Allele Matching between Siblings: Inhibitory KIR (iKIR) Mismatches Are Associated with Graft Versus Host Disease (GVHD) While Activatory KIR Matches (aKIR) and cGVHD Are Associated with Graft Versus Leukemia (GVL).

Klara Dalva, MD, Funda Gungor, Bcs, Ender Soydan Akcaglayan, MD, Meral Beksac, MD

Blood (2006) 108 (11): 2912.

https://doi.org/10.1182/blood.V108.11.2912.2912

Published: 2006

Journal Articles

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

Meral Beksac, MD, Ender Soydan, MD, Selami Kocak Toprak, MD, Merih Kizil, MD, Gulsah Kaygusuz, MD, Isinsu Kuzu, MD

Blood (2005) 106 (11): 5117.

https://doi.org/10.1182/blood.V106.11.5117.5117

Published: 2005

Journal Articles

The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.

Pervin Topcuoglu, MD, Mutlu Arat, MD, Tugce Bolukbasi, MD, Ender Soydan, MD, Yesim Ozer, MD, Muhit Ozcan, MD, Gunhan Gurman, MD, Taner Demirer, MD, Hamdi Akan, MD, Meral Beksac, MD, Onder Arslan, MD, Osman Ilhan, MD

Blood (2004) 104 (11): 5146.

https://doi.org/10.1182/blood.V104.11.5146.5146

Published: 2004

NARROW

Post-Induction Undetectable Minimal Residual Disease at 10 -5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells

CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity Via C-Maf-Mediated Interactions with Bone Marrow Stromal Cells (BMSCs)

Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide (T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma.

Two Independent Effects of Immunoglobulin-Like Receptor (KIR) Allele Matching between Siblings: Inhibitory KIR (iKIR) Mismatches Are Associated with Graft Versus Host Disease (GVHD) While Activatory KIR Matches (aKIR) and cGVHD Are Associated with Graft Versus Leukemia (GVL).

Marrow Plasma Cell Immunohistochemical Expression Profiles of Cyclins (A, D1, D2, D3), Cyclin Dependent Kinase Inhibitors (p16, p21) and Ki67: Predictors of Survival in Patients with Multiple Myeloma.

The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only